Allopurinol Crescent

Quick links

Choose a section

Quick links to important sections

Advertisements

Allopurinol Crescent

Advertisements
Advertisements

Overview of Allopurinol Crescent

Property Description
Active Ingredient Allopurinol
Form Oral Solid Preparation (Tablet)
Pharmacological Class Anti-hyperuricemic Agent, Xanthine Oxidase Inhibitor (XOI)
General Purpose Controlling chronic elevated uric acid levels (hyperuricemia)
Origin Synthetic Compound

The product Allopurinol Crescent is a specific presentation of the generic medicine Allopurinol, a widely available prescription-only medication. This drug is classified as a Xanthine Oxidase Inhibitor (XOI), a specific type of enzyme inhibitor. Its primary role is maintenance therapy, focusing on managing the underlying metabolic cause of chronic high urate levels.

Allopurinol: Composition and Pharmacological Action

The active ingredient is Allopurinol, a synthetic compound chemically categorized as a purine analog. It is consistently supplied as an oral solid preparation, typically a tablet, intended for oral administration. Unlike some older therapeutic agents, the core principle of Allopurinol is metabolic control: it works by interacting with and inhibiting the enzyme xanthine oxidase. This action directly lowers the concentration of uric acid in the blood and urine, a mechanism of action that is well-established in clinical practice.

General Purpose of an XOI in Chronic Management

As an XOI, the general purpose of Allopurinol is to significantly reduce the production of uric acid, thereby achieving and maintaining a controlled, low serum urate concentration. This goal is critical in managing patients with established hyperuricemia. By consistently inhibiting the key enzyme responsible for synthesis, the medication aids in preventing the chronic accumulation and subsequent crystallization of uric acid within tissues.

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Allopurinol Crescent?

Possible Side Effects and Safety Information

Allopurinol Crescent is generally well-tolerated, but like all medications, it can cause side effects. It is important to know which are common and which may indicate a serious reaction.


Common Side Effects

Commonly reported side effects are usually mild and may include nausea, diarrhea, drowsiness, and the temporary increase in gout attacks when treatment is first initiated. Gastrointestinal issues may be reduced by taking the medication with food. You should not drive or operate heavy machinery until you know how this medication affects you, particularly due to the risk of drowsiness.


Serious Side Effects

Though rare, allopurinol can cause serious, potentially life-threatening reactions. Stop taking the medication immediately and seek emergency medical attention if you experience any of the following:

  • Severe Skin Reactions: This includes Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Symptoms can start as a rash, fever, flu-like symptoms, and progress to blistering, peeling skin, or sores in the mouth, eyes, or genital area.
  • Liver Problems: Signs include persistent nausea, loss of appetite, dark urine, pale stools, or jaundice (yellowing of the skin or whites of the eyes).
  • Kidney Problems: Symptoms such as a change in the amount or frequency of urination, swelling in the feet or lower legs, and blood in the urine.
  • Allergic Reaction: Swelling of the face, lips, tongue, or throat, or difficulty breathing.

Drug Interactions and Precautions

Allopurinol can interact with other medications, potentially altering their effects or increasing the risk of adverse reactions. Key interactions include:

  • Immunosuppressants (e.g., azathioprine, mercaptopurine): Allopurinol can significantly increase the levels of these drugs, requiring a dose reduction and close monitoring.
  • Blood Thinners (e.g., warfarin): The risk of bleeding may be increased, necessitating closer INR monitoring.
  • Antibiotics (e.g., ampicillin, amoxicillin) or Diuretics (e.g., thiazides): Concomitant use may increase the risk of developing a skin rash.

Inform your healthcare provider of all prescription and nonprescription medications, vitamins, and herbal products you are taking. Your doctor may perform regular blood tests to check kidney and liver function, particularly during the initial phase of treatment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the expected manifestations and required emergency actions for an Allopurinol Crescent overdose. Documented clinical signs of overdose may include nausea, vomiting, diarrhea, and dizziness.

Severe Outcomes and Help-Seeking

Ingestion of quantities significantly exceeding the prescribed dose is associated with serious outcomes. The most severe consequence documented is acute renal failure and uric acid nephropathy, which can result from massive xanthine crystal deposition. Regulatory guidance mandates that patients or caregivers must seek immediate medical attention or contact emergency services immediately upon any known or suspected overdose exposure, particularly when severe symptoms occur. This immediate action is required due to the potential for life-threatening renal damage.

Management and Monitoring

Management procedures are described as symptomatic and supportive treatment, as no specific antidote is known for this medication. Supportive measures include adequate hydration to maintain diuresis, and in severe cases of massive intoxication, hemodialysis may be utilized for drug removal. Hospital monitoring is required following exposure, with specific attention given to the monitoring of renal function. Regulatory information notes that patients with pre-existing impaired renal function are at an increased risk for more severe outcomes following an overdose.

Advertisements

Therapeutic Uses of Allopurinol Crescent

Allopurinol Crescent is generally used as a foundational, long-term treatment to manage conditions arising from chronic high levels of uric acid (hyperuricemia), focusing exclusively on preventing symptomatic and structural complications. This medication is commonly prescribed for three main therapeutic objectives.


Key Therapeutic Applications

This medication is primarily used to address the conditions associated with chronic gout, is applied in addressing the prophylactic support relevant to recurrent uric acid kidney stones, and is relevant in contexts marked by increased discomfort or tension for oncology patients at risk of severe uric acid elevation. Its core therapeutic benefit contributes to easing the overall symptom load related to recurrent inflammatory joint episodes, which are symptoms related to inflammatory or irritative states like pain and swelling.

This supportive use assists with maintaining functional stability and supports the patient during difficult episodes by easing distress related to heightened systemic burden during critical treatment phases. The drug is commonly used across conditions presenting with recurrent episodes involving uric acid in the urinary system.


Quick Fact: Relief for Recurrent Pain The medicine is considered relevant and applied to managing symptoms that become more disruptive during flare-ups, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Allopurinol Crescent?

The eligibility profile for Allopurinol Crescent is strictly defined by regulatory documents, distinguishing between populations permitted use, those with restrictions, and those for whom the medicine is contraindicated.

Eligibility Scope

Category Eligibility Status (Based on Official Regulatory Labeling)
Populations for whom use is allowed Adults with chronic high uric acid levels (hyperuricemia) or recurrent kidney stones.
Populations for whom use is not recommended Individuals of Han Chinese, Thai, or Korean descent who are known to carry the *HLA-B58:01 allele** due to increased risk of severe skin reactions.
Populations for whom use is contraindicated Patients with a documented known hypersensitivity (allergy) to Allopurinol.
Age-related eligibility rules Use in children under 15 years is restricted to specific conditions like malignancy-associated hyperuricemia or inherited enzyme disorders. Older adults require lower starting doses and careful monitoring.
Condition-specific eligibility rules Patients with impaired renal function or impaired hepatic function are eligible only under conditional circumstances requiring dosage adjustments.
Pregnancy and lactation eligibility status Use during pregnancy and lactation is not recommended due to official advisories.
Eligibility-related restrictions Treatment is not recommended for asymptomatic hyperuricemia alone and must not be started during an acute attack of gout.

Connection to the overall eligibility profile

Regulatory documents establish absolute prohibitions for individuals with known drug allergies and those experiencing an acute gout attack. Furthermore, the profile sets forth conditional eligibility for populations with organ impairment and restricts use in pediatric, pregnant, and nursing populations, defining the official patient eligibility based on regulatory criteria.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Allopurinol Crescent (Allopurinol) is formally documented by regulatory authorities and centers on pharmacokinetic and pharmacodynamic mechanisms. The primary pharmacokinetic interaction is due to Allopurinol’s role as a Xanthine Oxidase Inhibitor, which prevents the metabolic inactivation of certain co-administered medicines.

Contraindicated Combinations and Exposure Modification

Co-administration with the uricase enzyme Pegloticase or the chemotherapy agent Capecitabine is designated for avoidance or discontinuation in official labeling. Due to inhibited metabolic clearance, co-administration with cytotoxic drugs like Mercaptopurine and Azathioprine requires a mandatory dose reduction of the co-administered agent to prevent documented severe toxicity.

Exposure-modifying interactions are also noted for Cyclosporine and Theophylline, whose plasma concentrations are documented to be increased, requiring therapeutic monitoring. Conversely, co-administration with Probenecid or high-dose Salicylates may accelerate the clearance of Allopurinol’s active metabolite, potentially decreasing its therapeutic effect.

Risk-Enhancing and Timing-Based Interactions

Pharmacodynamic interactions involve an increased risk of severe hypersensitivity reactions when combined with Thiazide Diuretics or ACE Inhibitors, especially in patients with impaired renal function. An increased frequency of skin rash is reported with Ampicillin or Amoxicillin. Finally, a mandatory 3-hour interval is required when administering Allopurinol alongside Aluminum Hydroxide to prevent interference with absorption.

Advertisements

Mechanism of Action

The action of Allopurinol (Allopurinol Crescent) is an enzyme-mediated biological process that influences the body's primary purine degradation pathway.

Targeted Enzyme Inhibition (Xanthine Oxidase)

The mechanism involves the inhibition of the enzyme Xanthine Oxidase (XO), primarily by the active metabolite Oxypurinol. This molecular interference blocks the final steps of the purine catabolism pathway, halting the conversion of purine precursors (Hypoxanthine and Xanthine) into Uric Acid. The enzymatic blockade is achieved, resulting in a continuous suppression of Uric Acid synthesis.

Modulation of Uric Acid Saturation Dynamics

By suppressing Uric Acid production, the drug reduces the overall Systemic Urate Load, which can shift the concentration in the plasma toward the saturation point. This physiological consequence shifts the chemical equilibrium to favor the dissolution and mobilization of deposited Monosodium Urate (MSU) crystals from tissues back into the bloodstream. The physical clearance of these crystalline deposits alters the tissue environment by removing the precipitated solid urate.

Advertisements

Dosage and Administration Information

Allopurinol Crescent is provided for administration via the oral route (tablet) for chronic maintenance, though the active substance, allopurinol, is also officially approved for intravenous (IV) use in hospital settings for specific scenarios where oral intake is not tolerated.

Official Dosing and Titration

Therapy is initiated with a low starting dose, commonly 100 mg once daily. The official dosing schedule dictates a gradual titration, typically increasing the dose in 100 mg increments at weekly intervals, adjusted until a target serum urate concentration is achieved. The standard adult maintenance range is between 100 mg and 900 mg daily, though the maximum daily oral dose is generally limited to 800 mg.

Frequency and Context

Doses up to 300 mg are typically taken once daily. However, any total daily dose exceeding 300 mg must be administered in divided doses to enhance gastrointestinal tolerability. The oral tablet must be taken after meals. If a scheduled dose is missed, instructions state not to double the subsequent dose.

Special Procedural Requirements

A key procedural instruction requires patients to maintain a high fluid intake sufficient to ensure a daily urinary output of at least 2 liters. Furthermore, mandatory dose reductions are required for patients with renal impairment, with specific dosage schedules prescribed for varying degrees of creatinine clearance (CrCl) and for those undergoing dialysis.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Summary

Clinical research on allopurinol primarily focuses on its established role as a xanthine oxidase inhibitor, which reduces the production of uric acid (urate). Trials consistently demonstrate that the compound is effective at lowering serum urate levels to therapeutic targets, which is the foundational goal for managing conditions like gout and preventing urate-related complications.

Investigation of Chronic Kidney Disease (CKD)

Recent randomized controlled trials (RCTs) have specifically investigated the hypothesis that lowering uric acid levels with allopurinol could slow the progression of CKD in both adult and pediatric populations. The majority of these large-scale studies reported that, despite achieving significant and sustained reductions in uric acid concentration, allopurinol did not demonstrably slow the decline in estimated glomerular filtration rate (eGFR) or modify the progression of kidney disease over the follow-up periods assessed. These findings suggest that elevated uric acid may often be a consequence, rather than a direct causal factor, in CKD progression.

Cardiovascular Outcomes

Research has also explored the potential influence of the compound on cardiovascular endpoints, given the association between high uric acid levels and cardiovascular risk factors. A systematic review and meta-analysis combining multiple RCTs evaluated the compound for secondary prevention in patients with cardiovascular disease. The analysis reported that allopurinol treatment was not associated with a significant reduction in cardiovascular death or all-cause death when compared to placebo or usual care. Limited data from smaller, earlier trials suggested a possible protective effect in specific high-risk subgroups, but these observations require further confirmation from subsequent large RCTs.

Safety and Tolerability

Allopurinol is generally considered well-tolerated, though serious side effects, such as a potentially life-threatening hypersensitivity syndrome, are a known, albeit rare, risk. Adverse events commonly reported in clinical trials are mild to moderate and often involve gastrointestinal upset or skin rash. Genetic markers, such as the HLA-B58:01* allele, are associated with a significantly increased risk of severe cutaneous reactions, underscoring the importance of individual patient risk assessment.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Allopurinol Crescent (FAQ)


Q: How quickly does Allopurinol Crescent start working to lower uric acid?

A: Official drug information indicates that the initial reduction of serum urate levels typically begins within 2 to 3 days of starting therapy. Achievement of the full effect on serum urate concentration is often reached within 7 to 14 days of continuous treatment, based on regulatory data.


Q: Are there any common foods or drinks that interact badly with Allopurinol Crescent?

A: According to the official product information, there are no known interactions between allopurinol and common foods or drinks. Taking the tablet after a meal is generally noted as a way to help reduce the possibility of stomach side effects like nausea or upset.


Q: Can you take Allopurinol Crescent with common over-the-counter pain relievers like ibuprofen?

A: Regulatory information states that allopurinol can generally be taken with common over-the-counter anti-inflammatory medicines and pain relievers such as ibuprofen or paracetamol (acetaminophen). Patients are generally advised to discuss all medications with their healthcare provider, as circumstances can vary.


Q: Does Allopurinol Crescent interact with any common herbal supplements?

A: There is not enough official information to confirm the safety of taking allopurinol with most herbal supplements, as these are not tested as rigorously as prescription medicines. Regulatory advice emphasizes the importance of informing a healthcare provider of all herbal remedies and supplements being used.


Q: What is the typical time frame to see full benefits from taking Allopurinol Crescent?

A: While the drug lowers uric acid quickly, studies show that it may require several months of continuous therapy to achieve the full clinical benefit. This time frame allows the body to reduce the total load of uric acid and mobilize crystalline deposits, contributing to the management of gout symptoms.


Q: Are there any known severe or rare side effects associated with Allopurinol Crescent?

A: Yes, official labeling reports that, in addition to common side effects, rare but severe reactions can occur. These documented rare side effects include blood disorders (such as aplastic anemia), significant liver damage (hepatotoxicity), and various other effects like headache or a temporary change in taste.


Q: Does Allopurinol Crescent affect fertility in men or women?

A: Regulatory documents indicate that rare cases of temporary infertility and impotence in men have been reported while taking allopurinol. However, studies have not conclusively confirmed that the drug is the direct cause of these reproductive issues.


Q: Are there any long-term side effects of taking Allopurinol Crescent for many years?

A: Allopurinol is intended for chronic, long-term use. Side effects that occur over time can relate to the organs it affects, such as potential renal failure or liver damage. Monitoring kidney and liver function with regular blood tests is part of standard long-term care for this medication.


Q: Is Allopurinol Crescent a type of chemotherapy drug?

A: No. Allopurinol is formally classified as an Anti-gout Agent and a Xanthine Oxidase Inhibitor (XOI), meaning it works by blocking an enzyme. However, the drug is frequently used to prevent high uric acid levels that are often caused by the death of cells during certain types of cancer treatments.


Q: Does Allopurinol Crescent cause weight gain or loss?

A: The official labeling does not list weight change as a common side effect of allopurinol. However, among the rare side effects reported in patient populations, both unusual weight gain or weight loss have been noted.


Q: What are the alternatives if someone cannot tolerate Allopurinol Crescent?

A: Official drug information suggests several alternatives for chronic gout management. These include other enzyme inhibitors like Febuxostat, Uricosuric agents such as Probenecid, which help the kidneys excrete uric acid, and powerful enzyme therapies like Pegloticase for the most severe cases.


Q: How significant is the risk of the severe skin reaction (SJS/TEN) with Allopurinol Crescent?

A: The official risk of the severe skin reactions known as SJS/TEN is generally low, estimated at approximately 1 to 6 per 10,000 new users in the general population. However, regulatory warnings emphasize that this risk is significantly higher (up to 10 times) in specific Asian ethnic groups who carry the *HLA-B58:01 allele**.


Q: What research evidence supports the use of Allopurinol Crescent for kidney stones?

A: Allopurinol is an approved therapy for the management of recurrent uric acid stones. It is also sometimes recommended as a second-line therapy for certain types of calcium oxalate stones in patients with documented high levels of uric acid in their urine (hyperuricosuria).


Q: How is Allopurinol Crescent eliminated from the body?

A: According to the official pharmacokinetics information, allopurinol and its main active form, oxipurinol, are primarily eliminated through the kidneys. Both substances are filtered out of the bloodstream and excreted from the body in the urine.


Q: What is the half-life of Allopurinol Crescent in the body?

A: Allopurinol (the parent drug) has a short half-life of only 1 to 3 hours. However, its primary active metabolite, oxipurinol, which performs most of the drug's work, has a much longer half-life, usually ranging from 15 to 20 hours.


Q: What does the latest research say about the effectiveness of Allopurinol Crescent?

A: Latest clinical trials and systematic reviews consistently show that allopurinol is a highly effective medication. These studies indicate that most participants treated with allopurinol successfully achieve their target serum urate level, a primary goal of therapy.


Q: What specific conditions does the drug Allopurinol Crescent help to manage?

A: Official drug indications state that allopurinol is used to manage chronic gout (including cases with tophi), recurrent uric acid kidney stones, and hyperuricemia associated with cancer treatment to prevent complications like tumor lysis syndrome.


Q: Can I drink alcohol in moderation while taking Allopurinol Crescent?

A: Regulatory documents suggest that individuals should limit alcohol consumption during treatment. This is because alcohol can potentially increase the risk of side effects such as drowsiness or other nervous system effects caused by allopurinol.


Q: Are there specific instructions for storing Allopurinol Crescent?

A: Official guidelines provide specific disposal instructions. Unused or expired allopurinol should not be flushed down the toilet or thrown away in household garbage. To ensure environmental protection, instructions for proper drug disposal should be obtained from a pharmacist or healthcare professional.


Q: What is the main reason doctors prescribe Allopurinol Crescent?

A: The main regulatory indication for Allopurinol is the management of chronic hyperuricemia—or persistently high levels of uric acid in the blood—to prevent its associated complications. This underlying purpose makes it the foundational treatment for chronic gout and for preventing uric acid-related kidney issues.


Q: Is Allopurinol Crescent used for anything other than gout?

A: Yes, regulatory documents list uses beyond chronic gout management. It is approved to treat recurrent uric acid kidney stones and for managing hyperuricemia related to certain cancer therapies in both adults and, for specific conditions, children.


Q: Is it normal to feel a gout flare-up right after beginning treatment with Allopurinol Crescent?

A: Yes, official safety information lists a temporary increase in gout attacks as a common side effect when treatment is first initiated. This is a recognized occurrence as the drug begins to break down uric acid deposits and the crystals mobilize.


Q: Is it true that Allopurinol Crescent can cause skin rash, and when does it usually happen?

A: Official safety documents confirm that a skin rash is a common adverse event. While a specific onset time is not detailed, these reactions typically occur early in the course of treatment before progressing to the rare, severe forms if not recognized quickly.


Q: Why do doctors sometimes prescribe Allopurinol Crescent for people undergoing cancer treatment?

A: The drug is indicated for use during cancer treatment to prevent hyperuricemia (high uric acid) and its complications. This is necessary because certain cancer therapies cause a rapid breakdown of cells, which releases large amounts of purines that the body then converts into uric acid.


Q: How long do most people need to stay on Allopurinol Crescent treatment?

A: Regulatory documents describe Allopurinol as a maintenance therapy for managing chronic conditions like gout and hyperuricemia. This classification suggests that the drug is typically intended for long-term, continuous use to keep uric acid levels controlled, rather than a short-term course.


Q: Can children or adolescents use Allopurinol Crescent for certain conditions?

A: The official labeling confirms that use in children under 15 years is restricted to specific, serious conditions. These include hyperuricemia associated with cancer treatment or certain inherited enzyme disorders that lead to high uric acid production.


Q: Can people with mild heart failure safely use Allopurinol Crescent?

A: Regulatory documents address eligibility based on organ function, requiring mandatory dose reductions for patients with impaired renal function or impaired hepatic function. While heart failure is not an absolute contraindication, its management would depend on the patient's overall health and the status of their liver and kidneys.


Q: What is the difference between allopurinol and the specific Allopurinol Crescent brand?

A: Allopurinol Crescent is a specific presentation of the generic medicine allopurinol. Regulatory information establishes that the active ingredient, mechanism of action, and therapeutic purpose are identical to the generic compound, with differences typically relating to the manufacturer and specific product formulation.


Q: Is Allopurinol Crescent safe for older adults or seniors?

A: Yes, official labeling confirms that older adults can use the medication, but it mandates specific instructions. They require lower starting doses and should receive careful and frequent medical monitoring, particularly concerning kidney and liver function.


Q: Does Allopurinol Crescent affect kidney function over time?

A: Official warnings require mandatory dose reductions for patients with impaired renal function, indicating a need for caution. The drug is eliminated by the kidneys, and monitoring is typically used to detect any potential changes in function during long-term treatment.


Q: What happens if you suddenly stop taking Allopurinol Crescent?

A: Sudden cessation of this medication would likely reverse its therapeutic benefit. Because the drug is a chronic maintenance therapy, stopping it would cause the underlying hyperuricemia to return, potentially leading to an increase in gout flares or the re-formation of uric acid crystals.

Advertisements

How should Allopurinol Crescent be stored and disposed of?

Storage and Handling

Allopurinol tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept strictly from freezing and should not be stored above 25 C. To maintain stability, the tablets require protection from environmental factors: they must be stored in a dry place and protected from light.

Storage Requirement Official Condition
Container Rule Store in the original, tightly closed container.
Child Safety Must be kept out of the sight and reach of children.
Temperature Limit Do not freeze or store above 25 C

Disposal Instructions

Unused or expired Allopurinol should not be disposed of in household waste or flushed down the toilet. Patients are required to ask a pharmacist or healthcare professional for instructions on how to properly discard the medicine, as these disposal measures are necessary to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allopurinol Crescent found in:

A-Z Index: